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The hypermethylation of the “CpG islands” and histone
deacetylation have been considered key epigenetic
mechanisms in several types of cancer. Despite hypo-
methylating agents are already used in the treatment of
some subtypes of Myelodysplastic Syndromes (MDS),
the role of ,histone deacetylase inhibitors in hematologi-
cal and solid tumors is still unclear.
With this work we intend to evaluate the potential
therapeutic effect of the histone deacetylase inhibitor,
Trichostatin A (TSA), in MDS, Chronic Lymphocytic
Leukemia (CLL) and in hepatocellular carcinoma (HCC).
For this, the cell lines EHEB (B-CLL), F36P (MDS)
and HUH-7 (HCC were maintained in culture in
absence and presence of TSA and/or Decitabine (DEC),
a demethylating drug. The density and cell viability was
assessed using Trypan Blue and/or Alamar test. Cell
death was evaluated by flow cytometry using Annexin V
and optic microscopy.
Our results show that epigenetic modulators, TSA and
DEC, induce a decrease in cell proliferation and viability
in a dose, time, administration squeme and cell type
dependent manner, inducing cell death by apoptosis.
B e s i d e sT S Aw a sa l s om o r ee f f e c t i v ei nm o n o t h e r a p y ,
when administered to cells 3/4 hours before than DEC,
or in a daily dose it was observed an increase in the
cytotoxic effect. On the other hand, MDS seems to be
the less sensitive cells and the higher cytotoxic effect is
achieved earlier and at lower doses in HUH-7 cells than
in EHEB cells, for the same drug concentration.
This study suggests that histone deacetylation may
become a new therapeutic approach in cancer. However,
the schedule of drugs administration and cell type may
interfere with their therapeutic efficacy.
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